

Appendix No. 1 to the Test certificate ML 2778/22

Documentation for the sample ML 2778/22




Figure 1: Tested sample PhenoGel Capsules SLEEP, batch: B172022253 (ML 2778/22)

End of appendix

Appendix No. 1 to the Test Certificate**LN 2824/22**

Testing method: Results for individual analytes from the sum are obtained by the method KM 21: Detection, identification and determination of cannabinoids, screening of impurities and degradation product by LC-MS method (see Test certificate ML 2778/22).

Test results:

Analyte	Result	Expanded uncertainty	Units	Testing method	Note
sum of detected cannabinoids*	3,88	0,39	% (w/w)	KM 21	X

*includes CBD, CBDA, Δ^9 -THC, Δ^8 -THC, Δ^9 -THCA-A, CBN, CBNA, CBG, CBGA, CBDV, CBDVA, CBC, CBCA, Δ^9 -THCV, THCVA, CBL, CBLA, CBT and CBE; the results for each analyte are given in the **Test certificate ML 2778/22 - PhenoGel Capsules SLEEP**

Expanded uncertainty was calculated using coverage factor $k = 2$ corresponding to a coverage probability of approximately 95%. Uncertainty was calculated and stated according to the EA-4/16 and manual Kvalimetrie 11 (issued by EURACHEM CZ). Uncertainty of sampling is not covered. Compliance is evaluated with respect to the uncertainty of test result according to the Guide ILAC-G8.

The results given herein apply only to the test sample as received. This certificate shall not be reproduced except in full, without written approval of the Laboratory. The certificate does not substitute any other legal document. Laboratory is not responsible for information supplied by customer, if such information can affect the validity of results.

The End of Appendix